Regeneron eyes prevention nod for COVID-19 antibody cocktail with simpler injection Vaccitech, the company that developed the AstraZeneca COVID-19 shot, files for a Nasdaq IPO COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO Vesta Healthcare pulls in $65M in growth capital backed by Deerfield, Kaiser Permanente Italian test maker DiaSorin puts down $1.8B for Luminex in diagnostics tie-up With variants spreading, Eli Lilly cuts solo COVID-19 antibody out of its U.S. supply deal FDA joins Europe in probing rare blood clots after Johnson & Johnson's COVID-19 vaccine COVID-19 tracker: Asthma drug reduces recovery time; European countries grapple with AstraZeneca vaccine decisions Sanofi's latest vaccine plan? A €400M Singapore factory full of 'boundary-pushing' tech London healthcare firm snaps up Velocity Clinical Research after COVID-19 changes the trial paradigm Experts say CMS taking a wait-and-see approach on price transparency amid mixed hospital compliance Featured Story | By Angus Liu Regeneron’s Roche-partnered COVID-19 antibody cocktail, authorized to thwart disease progression in already sick patients, has come up with new data showing it can prevent the disease altogether in healthy people at a lower dose in a more convenient injection. read more |
| |
|---|
|
Top Stories By Ben Adams U.K. vaccine and cancer biotech Vaccitech, now famous (and perhaps in some quarters, infamous) for its tech that delivered the AstraZeneca-University of Oxford vaccine, is gunning for an IPO. read more By Annalee Armstrong French biotech Valneva, which has developed a lineup of traveler vaccines and is starting a late-stage COVID vax effort, is seeking to level up to the Nasdaq with a $100 million IPO. read more By Heather Landi Vesta Healthcare, a digital health platform focused on home-based care, pulled in $65 million in growth capital to help it expand in other states and develop partnerships with home care agencies. Deerfield Management Company, Oak HC/FT and Kaiser Permanente Ventures backed the financing round. read more By Conor Hale The Italian in vitro diagnostic developer DiaSorin has plunked down about $1.8 billion for molecular test maker Luminex and its portfolio of multiplexed assays and screeners for COVID-19. read more By Noah Higgins-Dunn The feds are bidding adieu to bamlanivimab alone. After the solo COVID-19 antibody drug fell short in lab testing against coronavirus variants, Eli Lilly has rejigged its deal with the U.S. government to only cover a combination of bamlanivimab and etesevimab. read more By Eric Sagonowsky Drug regulators in Europe last week flagged rare but “serious” cases of blood clots in people who had received Johnson & Johnson’s COVID-19 vaccine. But it’s not just European regulators taking a close look at the shot’s safety profile—the FDA is, too. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky An asthma drug showed reduced recovery time for COVID-19 patients at home in interim clinical results. Eli Lilly is ending its supply deal with the U.S. for its solo antibody drug bamlanivimab. Some European countries are facing tough decisions over who should be vaccinated with AstraZeneca's shot. And more headlines. read more By Fraiser Kansteiner Just weeks after Sanofi earmarked €600 million for a new flu shot factory, the company's blueprinting a €400 million, high-tech vaccine plant in Singapore. The new factory will be designed to turn out multiple vaccines at the same time—and could help respond to future pandemics, too. read more By Ben Adams U.K.-based healthcare venture firm GHO Capital has bought out siteless trial specialist Velocity Clinical Research from its D.C.-based VC owner NaviMed Capital. read more By Robert King Several studies have shown hospitals had a mixed record on compliance with a major price transparency rule, but experts say CMS has taken more of a wait-and-see approach on enforcement. read more |
